KLOW peptide stack: what the literature says about KPV + Lipoic + GHK-Cu + TB-500 together

What KLOW stands for and where the name came from

KLOW is a community-coined acronym for a four-component peptide stack circulating in research-protocol discussion since roughly 2022. The letters map to:

• K — KPV, the tripeptide Lys-Pro-Val
• L — Alpha-lipoic acid (ALA)
• O — GHK-Cu, the copper tripeptide glycyl-histidyl-lysine
• W — TB-500, the synthetic fragment of thymosin beta-4

The acronym does not appear in any peer-reviewed publication. It originated in r/Peptides protocol threads, where users assembled the stack around mechanism complementarity. KLOW is a protocol pattern, not a trial cohort.

The four components

KPV — anti-inflammatory tripeptide

KPV is the C-terminal tripeptide Lys-Pro-Val, the last three amino acids of alpha-melanocyte-stimulating hormone. Published research shows KPV acts as an anti-inflammatory signaling agent at the melanocortin-1 receptor, with documented effects in murine models of inflammatory bowel disease (Dalmasso et al., 2008, PMID 18394389) and skin inflammation. The supported mechanism is reduced NF-kB-driven cytokine production.

Doses in the published preclinical literature cluster around 0.5-1 mg/kg in rodent models. Human research-protocol references in community discussion typically cite 200-500 mcg daily, extrapolated from animal-model ranges rather than human trials.

Alpha-lipoic acid — antioxidant cofactor

Alpha-lipoic acid (ALA) is the odd one out: it is not a peptide. It is a sulfur-containing mitochondrial cofactor with documented antioxidant activity, validated in randomized trials for diabetic peripheral neuropathy at oral doses of 600-1800 mg daily (Ziegler et al., PMID 16998490). In a stack built around repair signaling, ALA is the redox-buffer component — it scavenges reactive oxygen species and regenerates vitamin C and glutathione.

Its evidence base is substantially deeper than the three peptide components, but the indications studied are metabolic, not tissue-repair.

GHK-Cu — copper tripeptide for tissue repair

GHK-Cu (glycyl-histidyl-lysine bound to copper) is one of the most-studied peptides in the dermal-regeneration literature. Pickart's 2008 review (PMID 18204724) summarizes 40-plus years of work on its role in collagen synthesis, antioxidant signaling, and wound contraction. The mechanism: GHK-Cu binds copper and delivers it to fibroblasts, upregulating collagen and elastin synthesis and activating antioxidant pathways including SOD2. See the GHK-Cu peptide page for the vendor-grade audit.

Topical formulations in the literature cluster at 0.1-2% concentration; subcutaneous research-protocol references typically cite 1-3 mg daily, again extrapolated rather than trial-validated in humans.

TB-500 — thymosin beta-4 fragment

TB-500 is a synthetic acetylated peptide corresponding to amino acids 17-23 of human thymosin beta-4 (in some vendor SKUs; others sell different fragments under the same name). Its mechanism is actin sequestration: TB-500 binds G-actin and modulates cytoskeletal dynamics during cell migration, the rate-limiting step in wound repair. Preclinical work spans cardiac repair (Goldstein 2009, PMID 19207036), corneal wound healing, and ischemic-injury recovery; no Phase 3 human trial has reported in any indication.

Research-protocol dose references cluster at 2-10 mg weekly. See the BPC-157 and TB-500 literature read for the deeper TB-500 review and the SKU-variance issue.

What the literature actually shows about the combination

The honest answer: no published peer-reviewed trial has tested the four-component KLOW stack. The literature base is entirely single-compound. PubMed returns zero results for the combination of KPV with GHK-Cu with TB-500 with alpha-lipoic acid, and that is the actual state of the evidence as of this writing.

Each component has its own evidence base:

• KPV in inflammatory bowel disease models and skin inflammation (Dalmasso 2008, PMID 18394389)
• Alpha-lipoic acid in diabetic neuropathy randomized trials (Ziegler et al., multiple)
• GHK-Cu in dermal wound healing and collagen synthesis (Pickart 2008, PMID 18204724)
• TB-500 / thymosin beta-4 in cardiac and corneal repair (Goldstein 2009, PMID 19207036)

The stack as a stack is a community-protocol assembly. That is not the same thing as "it does not work" — it is the precise statement that no controlled trial has tested whether the four together produce additive, synergistic, or interfering effects relative to any subset.

Why people stack them anyway

The community argument is mechanism complementarity: the four compounds target four different layers of the tissue-repair response.

• KPV quiets cytokine signaling (inflammation layer)
• ALA scavenges oxidative byproducts (redox layer)
• GHK-Cu drives matrix deposition (collagen layer)
• TB-500 modulates actin dynamics (cell migration layer)

In a textbook model of wound healing those four layers genuinely are distinct and sequential, so the stack design is internally coherent on paper. Whether the coherence translates into measurable outcomes in vivo is the gap the literature has not filled. The same critique applies to the BPC-157 + TB-500 combination and most other multi-peptide stacks: the mechanism stories are plausible, the trial data is not there.

How buyers actually use it

Two real patterns in r/Peptides discussion:

Pre-mixed single injection. Some vendors sell KLOW as a single vial delivering all four components in one draw. The appeal is one injection instead of four; the cost is sterility-at-mix-step risk, a single shared shelf-life window, and no per-component titration.

Separate vials, separate draws. Reconstituting four separate vials and dosing each on its own schedule preserves per-component control and stability tracking. The r/Peptides thread "KLOW injections vs individually dosing" surfaces the tradeoff in detail — the consensus there leans toward separate dosing for any protocol longer than 4-6 weeks.

ALA in particular is rarely included in a pre-mixed injectable stack; community protocols often inject the three peptides and dose ALA as an oral capsule.

What we'd want to see before recommending it

The editorial position: a controlled trial of the KLOW combination would need to demonstrate three things before this stack moves from community-protocol to evidence-supported.

1. Outcome data in a defined indication. Pick one — chronic wound healing, post-surgical recovery, tendon repair — and measure against placebo and against each component alone.
2. Pharmacokinetic interaction data. Does the actin-sequestration activity of TB-500 affect the cellular uptake of GHK-Cu? Does ALA's reducing activity affect copper binding in GHK-Cu? Plausible interactions exist; no one has measured them.
3. Safety signal across the four together. Each compound has a documented single-compound safety profile. Stack-level adverse-event data does not exist.

Until that work happens, KLOW is a community-protocol construction. The mechanism story is plausible enough to explain why the stack persists. The evidence base is not what is conventionally meant by "researched."

Related reading

• BPC-157 and TB-500 literature read — the structurally identical "two-compound stack, mechanism-complementarity argument, sparse clinical evidence" pattern, written up for the most-discussed alternative pair.
• GHK-Cu peptide page — the per-compound research read and vendor audit on GHK-Cu specifically.
• Peptide reconstitution guide — the BAC water and dose math reference for anyone reconstituting any KLOW component, whether pre-mixed or separately.
• Ascension Peptides legit page — the audit on the most-cited KLOW vendor in r/Peptides protocol threads.